A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 2166-2174

  Ujiie, Hideyuki ^a   Shibaki, Akihiko ^a   Nishie, Wataru ^a   Sawamura, Daisuke ^a   Wang, Gang ^a   Tateishi, Yasuki ^a   Li, Qiang ^a   Moriuchi, Reine ^a   Qiao, Hongjiang ^a   Nakamura, Hideki ^a   Akiyama, Masashi ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD45RB ANTIGEN; COLLAGEN TYPE 17 IMMUNOGLOBULIN G ANTIBODY; CYCLOSPORIN A; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; RAG2 PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; CD45 ANTIGEN; COLLAGEN TYPE 17; IMMUNOGLOBULIN G; NONFIBRILLAR COLLAGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLISTER; BULLOUS PEMPHIGOID; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOELECTRON MICROSCOPY; IMMUNOPATHOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; T CELL DEPLETION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; FEMALE; GENE TARGETING; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTOPENIA; METHODOLOGY; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ANTIGENS, CD45; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; LYMPHOPENIA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS;

EID: 77949889249     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903101     Document Type: Article

References (48)

1. Nishie, W., D. Sawamura, M. Goto, K. Ito, A. Shibaki, J. R. McMillan, K. Sakai, H. Nakamura, E. Olasz, K. B. Yancey, et al. 2007. Humanization of autoantigen. Nat. Med. 13: 378-383.
2. Taneja, V., and C. S. David. 2001. Lessons from animal models for human autoimmune diseases. Nat. Immunol. 2: 781-784.
3. Diaz, L. A., H. Ratrie, III, W. S. Saunders, S. Futamura, H. L. Squiquera, G. J. Anhalt, and G. J. Giudice. 1990. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J. Clin. Invest. 86: 1088-1094.
4. Giudice, G. J., D. J. Emery, and L. A. Diaz. 1992. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J. Invest. Dermatol. 99: 243-250.
5. Hopkinson, S. B., K. S. Riddelle, and J. C. Jones. 1992. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J. Invest. Dermatol. 99: 264-270.
6. Bédane, C., J. R. McMillan, S. D. Balding, P. Bernard, C. Prost, J. M. Bonnetblanc, L. A. Diaz, R. A. Eady, and G. J. Giudice. 1997. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J. Invest. Dermatol. 108: 901-907.
7. Ishiko, A., H. Shimizu, A. Kikuchi, T. Ebihara, T. Hashimoto, and T. Nishikawa. 1993. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J. Clin. Invest. 91: 1608-1615.
8. Zillikens, D., P. A. Rose, S. D. Balding, Z. Liu, M. Olague-Marchan, L. A. Diaz, and G. J. Giudice. 1997. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 109: 573-579.
9. Giudice, G. J., D. J. Emery, B. D. Zelickson, G. J. Anhalt, Z. Liu, and L. A. Diaz. 1993. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 151: 5742-5750.
10. Amagai, M., K. Tsunoda, H. Suzuki, K. Nishifuji, S. Koyasu, and T. Nishikawa. 2000. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest. 105: 625-631.
11. Olasz, E. B., J. Roh, C. L. Yee, K. Arita, M. Akiyama, H. Shimizu, J. C. Vogel, and K. B. Yancey. 2007. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J. Invest. Dermatol. 127: 2807-2817.
12. Nelson, K. C., M. Zhao, P. R. Schroeder, N. Li, R. A. Wetsel, L. A. Diaz, and Z. Liu. 2006. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J. Clin. Invest. 116: 2892-2900.
13. Nishifuji, K., M. Amagai, M. Kuwana, T. Iwasaki, and T. Nishikawa. 2000. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J. Invest. Dermatol. 114: 88-94.
14. Sitaru, C., S. Mihai, C. Otto, M. T. Chiriac, I. Hausser, B. Dotterweich, H. Saito, C. Rose, A. Ishiko, and D. Zillikens. 2005. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115: 870-878.
15. Shimizu, H., J. N. McDonald, A. R. Kennedy, and R. A. Eady. 1989. Demonstration of intra- and extracellular localization of bullous pemphigoid antigen using cryofixation and freeze substitution for postembedding immunoelectron microscopy. Arch. Dermatol. Res. 281: 443-448.
16. Shimizu, H., A. Ishida-Yamamoto, and R. A. Eady. 1992. The use of silver-enhanced 1-nm gold probes for light and electron microscopic localization of intra- and extracellular antigens in skin. J. Histochem. Cytochem. 40: 883-888.
17. Takae, Y., T. Nishikawa, and M. Amagai. 2009. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp. Dermatol. 18: 252-260.
18. Shibaki, A., A. Sato, J. C. Vogel, F. Miyagawa, and S. I. Katz. 2004. Induction of GVHD-like skin disease by passively transferred CD8+ T-cell receptor transgenic Tcells into keratin 14-ovalbumin transgenicmice. J. Invest. Dermatol. 123: 109-115.
19. Bianchi, L., S. Gatti, and G. Nini. 1992. Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids. J. Am. Acad. Dermatol. 27: 278.
20. Curley, R. K., and C. A. Holden. 1991. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin. Exp. Dermatol. 16: 68-69.
21. Thivolet, J., H. Barthelemy, G. Rigot-Muller, and A. Bendelac. 1985. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 325: 334-335. (Pubitemid 15157136)
22. Barthélémy, H., J. Thivolet, F. Cambazard, A. Bendelac, G. Mauduit, F. Granier, and A. Frappaz. 1986. [Cyclosporin in the treatment of bullous pemphigoid: preliminary study]. Ann. Dermatol. Venereol. 113: 309-313.
23. Chen, R., G. Ning, M. L. Zhao, M. G. Fleming, L. A. Diaz, Z. Werb, and Z. Liu. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108: 1151-1158.
24. Liu, Z., L. A. Diaz, J. L. Troy, A. F. Taylor, D. J. Emery, J. A. Fairley, and G. J. Giudice. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92: 2480-2488.
25. Liu, Z., G. J. Giudice, S. J. Swartz, J. A. Fairley, G. O. Till, J. L. Troy, and L. A. Diaz. 1995. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95: 1539-1544.
26. Jordon, R. E., S. Kawana, and K. A. Fritz. 1985. Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J. Invest. Dermatol. 85: 72s-78s.
27. Provost, T. T., and T. B. Tomasi, Jr. 1973. Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid. J. Clin. Invest. 52: 1779-1787.
28. Sitaru, C., S. Mihai, and D. Zillikens. 2007. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch. Dermatol. Res. 299: 1-8.
29. Aricha, R., T. Feferman, S. Fuchs, and M. C. Souroujon. 2008. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J. Immunol. 180: 2132-2139.
30. Sheng, J. R., L. Li, B. B. Ganesh, C. Vasu, B. S. Prabhakar, and M. N. Meriggioli. 2006. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J. Immunol. 177: 5296-5306.
31. + regulatory cells within the central nervous system. J. Immunol. 175: 3025-3032.
32. + regulatory T cells. J. Immunol. 179: 958-966.
33. Kaul, R., M. Shenoy, E. Goluszko, and P. Christadoss. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152: 3152-3157. (Pubitemid 24098013)
34. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184: 349-356.
35. Aoki-Ota, M., K. Tsunoda, T. Ota, T. Iwasaki, S. Koyasu, M. Amagai, and T. Nishikawa. 2004. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br. J. Dermatol. 151: 346-354.
36. Christadoss, P., M. Poussin, and C. Deng. 2000. Animal models of myasthenia gravis. Clin. Immunol. 94: 75-87.
37. b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur. J. Immunol. 25: 1951-1959.
38. Büdinger, L., L. Borradori, C. Yee, R. Eming, S. Ferencik, H. Grosse-Wilde, H. F. Merk, K. Yancey, and M. Hertl. 1998. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 102: 2082-2089.
39. Lin, M. S., C. L. Fu, G. J. Giudice, M. Olague-Marchan, A. M. Lazaro, P. Stastny, and L. A. Diaz. 2000. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J. Invest. Dermatol. 115: 955-961.
40. Thoma-Uszynski, S., W. Uter, S. Schwietzke, G. Schuler, L. Borradori, and M. Hertl. 2006. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J. Immunol. 176: 2015-2023.
41. Delgado, J. C., D. Turbay, E. J. Yunis, J. J. Yunis, E. D. Morton, K. Bhol, R. Norman, C. A. Alper, R. A. Good, and R. Ahmed. 1996. A common major histocompatibility complex class II allele HLA-DQB1p 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. USA 93: 8569-8571.
42. Xu, L., N. Robinson, S. D. Miller, and L. S. Chan. 2001. Characterization of BALB/c mice B lymphocyte autoimmune responses to skin basement membrane component type XVII collagen, the target antigen of autoimmune skin disease bullous pemphigoid. Immunol. Lett. 77: 105-111.
43. Sitaru, C., M. T. Chiriac, S. Mihai, J. Büning, A. Gebert, A. Ishiko, and D. Zillikens. 2006. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J. Immunol. 177: 3461-3468.
44. null mice. Blood 106: 1565-1573.
45. null mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182.
46. Kumar, P., H. S. Ban, S. S. Kim, H. Wu, T. Pearson, D. L. Greiner, A. Laouar, J. Yao, V. Haridas, K. Habiro, et al. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
47. Yajima, M., K. Imadome, A. Nakagawa, S. Watanabe, K. Terashima, H. Nakamura, M. Ito, N. Shimizu, M. Honda, N. Yamamoto, and S. Fujiwara. 2008. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 198: 673-682.
48. null (NOG) mice (hu-HSC NOG mice). Int. Immunol. 21: 843-858.